Omnio AB is a biopharmaceutical company that specializes in the development of innovative drug products. With a focus on the pro-inflammatory and immunoregulatory effects of the protein plasminogen, Omnio is dedicated to revolutionizing wound healing treatments. Through their extensive research and physician-led studies, they have discovered the enormous potential of recombinant plasminogen in treating chronic wounds.

Driven by the ambition to offer patients an effective alternative when bioactive treatment options are limited, Omnio aims to transform the current landscape of wound healing therapies. Their groundbreaking approach has the potential to significantly improve the lives of those suffering from chronic wounds. Led by a dedicated team of experts, including a knowledgeable management team and board of directors, Omnio is committed to bringing their innovative drug products to market.

By harnessing the power of pro-inflammatory and immunoregulatory mechanisms, Omnio is at the forefront of advancing wound healing treatments. Stay up to date with Omnio's progress by following them on LinkedIn. Copyright © Omnio 2023